Form 4: Cognition Therapeutics Director Granted 34,000 Restricted Stock Units

Ellen B. Richstone, a Director at Cognition Therapeutics Inc., was granted 34,000 restricted stock units, increasing her direct beneficial ownership to 58,500 shares.

Summary

• Ellen B. Richstone, a Director of Cognition Therapeutics Inc. (CGTX), acquired 34,000 shares of Common Stock on June 18, 2025.
• The acquisition was in the form of Restricted Stock Units (RSUs) granted at a price of $0.00 per share.
• Each RSU represents a contingent right to receive one share of the Issuer's Common Stock upon settlement.
• The RSUs are scheduled to vest in full on the earlier of June 18, 2026, or the date of the Issuer's next annual meeting of stockholders, subject to Ms. Richstone's continuous service as a director.
• Following this transaction, Ellen B. Richstone directly beneficially owns 58,500 shares of Cognition Therapeutics Inc. Common Stock.

Sentiment

Score: 7

Explanation: The grant of equity to a director is a positive signal, indicating alignment of interests between management/board and shareholders. It's a standard practice for director compensation.

Positives

• The grant of 34,000 Restricted Stock Units (RSUs) to Director Ellen B. Richstone aligns her interests with those of shareholders, as the value of the RSUs is tied to the company's stock performance.
• The increase in direct beneficial ownership to 58,500 shares demonstrates continued commitment from a key board member.

Negatives

• No direct negatives are apparent from this Form 4 filing, which primarily reports an equity grant to a director.

Risks

• This Form 4 filing does not contain information regarding specific company risks.

Future Outlook

The 34,000 Restricted Stock Units (RSUs) granted to Director Ellen B. Richstone are scheduled to vest in full on the earlier of June 18, 2026, or the date of the Issuer's next annual meeting of stockholders, subject to her continuous service as a director.

Industry Context

This Form 4 filing reports an individual insider transaction and does not provide broader industry context or trends.

Related Party Transactions

• This Form 4 filing reports a standard equity grant to a director as part of their compensation, which is a common related-party transaction in the context of corporate governance. No other specific related party dealings are disclosed.

Stakeholder Impact

• Shareholders: The equity grant to a director aligns their interests with shareholders, potentially encouraging decisions that enhance long-term stock value.

Next Steps

• Vesting of the 34,000 Restricted Stock Units (RSUs) on the earlier of June 18, 2026, or the date of the Issuer's next annual meeting of stockholders, subject to continuous service.

Key Dates

Keywords

Cognition Therapeutics, CGTX, SEC Form 4, Insider Transaction, Restricted Stock Units, RSU, Director Compensation, Equity Grant, Stock Ownership